BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 2012;32:199-213. [PMID: 21745318 DOI: 10.1111/j.1478-3231.2011.02579.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Muti LA, Pârvu AE, Crăciun AM, Miron N, Acalovschi M. Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension. Clujul Med 2015;88:140-5. [PMID: 26528062 DOI: 10.15386/cjmed-458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Li H. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00375-3. [PMID: 34344577 DOI: 10.1016/j.dld.2021.07.006] [Reference Citation Analysis]
3 Matsumoto M, Zhang J, Zhang X, Liu J, Jiang JX, Yamaguchi K, Taruno A, Katsuyama M, Iwata K, Ibi M, Cui W, Matsuno K, Marunaka Y, Itoh Y, Torok NJ, Yabe-Nishimura C. The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease. Free Radic Biol Med 2018;115:412-20. [PMID: 29274380 DOI: 10.1016/j.freeradbiomed.2017.12.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
4 Fleming MM, DeWane MP, Luo J, Zhang Y, Pei KY. Ascites: A marker for increased surgical risk unaccounted for by the model for end-stage liver disease (MELD) score for general surgical procedures. Surgery 2018;164:233-7. [PMID: 29705097 DOI: 10.1016/j.surg.2018.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
5 Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018;38:570-80. [PMID: 28921803 DOI: 10.1111/liv.13589] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 19.0] [Reference Citation Analysis]
6 Xuan R, Zhao X, Hu D, Jian J, Wang T, Hu C. Three-dimensional visualization of the microvasculature of bile duct ligation-induced liver fibrosis in rats by x-ray phase-contrast imaging computed tomography. Sci Rep 2015;5:11500. [PMID: 26212186 DOI: 10.1038/srep11500] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
7 Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis. 2012;59:874-885. [PMID: 22480795 DOI: 10.1053/j.ajkd.2011.12.032] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
8 Ni Y, Li JM, Liu MK, Zhang TT, Wang DP, Zhou WH, Hu LZ, Lv WL. Pathological process of liver sinusoidal endothelial cells in liver diseases. World J Gastroenterol. 2017;23:7666-7677. [PMID: 29209108 DOI: 10.3748/wjg.v23.i43.7666] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
9 Snowdon VK, Guha N, Fallowfield JA. Noninvasive evaluation of portal hypertension: emerging tools and techniques. Int J Hepatol. 2012;2012:691089. [PMID: 22720166 DOI: 10.1155/2012/691089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
10 Piekarska A, Berkan EK, Wójcik KM. Surveillance for portal hypertension in the course of liver cirrhosis. Clin Exp Hepatol 2018;4:49-54. [PMID: 29904721 DOI: 10.5114/ceh.2018.75954] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Arima J, Huang C, Rosner B, Akaishi S, Ogawa R. Hypertension: a systemic key to understanding local keloid severity. Wound Repair Regen 2015;23:213-21. [PMID: 25728259 DOI: 10.1111/wrr.12277] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
12 Hu DD, Chen Y, Bihi A, Li XM, Wang TL, Wang BE, Zhao XY. A new conversation between radiology and pathology-identifying microvascular architecture in stages of cirrhosis via diffraction enhanced imaging in vitro. PLoS One 2014;9:e87957. [PMID: 24504507 DOI: 10.1371/journal.pone.0087957] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
13 Yang L, Shen ZY, Wang RR, Yin ML, Zheng WP, Wu B, Liu T, Song HL. Effects of heme oxygenase-1-modified bone marrow mesenchymal stem cells on microcirculation and energy metabolism following liver transplantation. World J Gastroenterol 2017;23:3449-67. [PMID: 28596681 DOI: 10.3748/wjg.v23.i19.3449] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020;26:6111-40. [PMID: 33177789 DOI: 10.3748/wjg.v26.i40.6111] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Van der Graaff D, Kwanten WJ, Couturier FJ, Govaerts JS, Verlinden W, Brosius I, D'Hondt M, Driessen A, De Winter BY, De Man JG, Michielsen PP, Francque SM. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. Lab Invest 2018;98:1263-75. [PMID: 29326427 DOI: 10.1038/s41374-017-0018-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
16 Pourhoseini S, Seth RK, Das S, Dattaroy D, Kadiiska MB, Xie G, Michelotti GA, Nagarkatti M, Diehl AM, Chatterjee S. Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis. PLoS One 2015;10:e0116780. [PMID: 25658689 DOI: 10.1371/journal.pone.0116780] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
17 Licinio R, Losurdo G, Carparelli S, Iannone A, Giorgio F, Barone M, Principi M, Ierardi E, Di Leo A. Helicobacter pylori , liver cirrhosis, and portal hypertension: an updated appraisal. Immunopharmacology and Immunotoxicology 2016;38:408-13. [DOI: 10.1080/08923973.2016.1247855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Iwakiri Y, Groszmann RJ. Pathophysiology of Portal Hypertension. In: de Franchis R, Dell’era A, editors. Variceal Hemorrhage. New York: Springer; 2014. pp. 3-14. [DOI: 10.1007/978-1-4939-0002-2_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Iwakiri Y, Kim MY. Nitric oxide in liver diseases. Trends Pharmacol Sci. 2015;36:524-536. [PMID: 26027855 DOI: 10.1016/j.tips.2015.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 73] [Article Influence: 17.2] [Reference Citation Analysis]
20 Delgado MG, Gracia-sancho J, Marrone G, Rodríguez-vilarrupla A, Deulofeu R, Abraldes JG, Bosch J, García-pagán JC. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2013;305:G496-502. [DOI: 10.1152/ajpgi.00336.2012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
21 Maslak E, Gregorius A, Chlopicki S. Liver sinusoidal endothelial cells (LSECs) function and NAFLD; NO-based therapy targeted to the liver. Pharmacol Rep. 2015;67:689-694. [PMID: 26321269 DOI: 10.1016/j.pharep.2015.04.010] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
22 Kimer N, Wiese S, Mo S, Møller S, Bendtsen F. Advances in the treatment of portal hypertension in cirrhosis. Expert Rev Gastroenterol Hepatol 2016;10:961-9. [PMID: 26982499 DOI: 10.1586/17474124.2016.1166952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Bartneck M, Topuz F, Tag CG, Sauer-Lehnen S, Warzecha KT, Trautwein C, Weiskirchen R, Tacke F. Molecular response of liver sinusoidal endothelial cells on hydrogels. Mater Sci Eng C Mater Biol Appl 2015;51:64-72. [PMID: 25842109 DOI: 10.1016/j.msec.2015.02.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Eisinger K, Krautbauer S, Wiest R, Weiss TS, Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp Mol Pathol 2015;98:208-13. [PMID: 25595667 DOI: 10.1016/j.yexmp.2015.01.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
25 McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int. 2018;12:11-23. [PMID: 29075990 DOI: 10.1007/s12072-017-9826-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
26 Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf). 2017;5:104-112. [PMID: 28533908 DOI: 10.1093/gastro/gox010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
27 Huang D, Gibeley SB, Xu C, Xiao Y, Celik O, Ginsberg HN, Leong KW. Engineering liver microtissues for disease modeling and regenerative medicine. Adv Funct Mater 2020;30:1909553. [PMID: 33390875 DOI: 10.1002/adfm.201909553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
28 Drzewiecki K, Choi J, Brancale J, Leney-Greene MA, Sari S, Dalgiç B, Ünlüsoy Aksu A, Evirgen Şahin G, Ozen A, Baris S, Karakoc-Aydiner E, Jain D, Kleiner D, Schmalz M, Radhakrishnan K, Zhang J, Hoebe K, Su HC, Pereira JP, Lenardo MJ, Lifton RP, Vilarinho S. GIMAP5 maintains liver endothelial cell homeostasis and prevents portal hypertension. J Exp Med 2021;218:e20201745. [PMID: 33956074 DOI: 10.1084/jem.20201745] [Reference Citation Analysis]
29 Wiest R, Weiss TS, Danielyan L, Buechler C. Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study. J Clin Med 2021;10:2669. [PMID: 34204545 DOI: 10.3390/jcm10122669] [Reference Citation Analysis]
30 Iguchi H, Oda M, Yamazaki H, Yokomori H. Participation of aquaporin-1 in vascular changes and remodeling in cirrhotic liver. Med Mol Morphol 2013;46:123-32. [PMID: 23549977 DOI: 10.1007/s00795-013-0039-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Brusilovskaya K, Königshofer P, Lampach D, Szodl A, Supper P, Bauer D, Beer A, Stift J, Timelthaler G, Oberhuber G, Podesser BK, Seif M, Zinober K, Rohr-Udilova N, Trauner M, Reiberger T, Schwabl P. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United European Gastroenterol J 2020;8:1174-85. [PMID: 32878579 DOI: 10.1177/2050640620944140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Starlinger P, Pereyra D, Haegele S, Braeuer P, Oehlberger L, Primavesi F, Kohler A, Offensperger F, Reiberger T, Ferlitsch A, Messner B, Beldi G, Staettner S, Brostjan C, Gruenberger T. Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. Hepatology. 2018;67:1516-1530. [PMID: 29140542 DOI: 10.1002/hep.29651] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
33 Hidaka H, Iwakiri Y. Hepatic congestion leads to fibrosis: findings in a newly developed murine model. Hepatology 2015;61:428-30. [PMID: 25283276 DOI: 10.1002/hep.27550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
34 Zhou HY, Chen TW, Zhang XM, Wang LY, Zhou L, Dong GL, Zeng NL, Li H, Chen XL, Li R. The diameter of the originating vein determines esophageal and gastric fundic varices in portal hypertension secondary to posthepatitic cirrhosis. Clinics (Sao Paulo) 2012;67:609-14. [PMID: 22760900 DOI: 10.6061/clinics/2012(06)11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Casey S, Schierwagen R, Mak KY, Klein S, Uschner F, Jansen C, Praktiknjo M, Meyer C, Thomas D, Herath C, Jones R, Trebicka J, Angus P. Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation. J Clin Med. 2019;8. [PMID: 30934723 DOI: 10.3390/jcm8040419] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
36 Lu J, Zhao YL, Zhang XQ, Li LJ. The vascular endothelial growth factor signaling pathway regulates liver sinusoidal endothelial cells during liver regeneration after partial hepatectomy. Expert Rev Gastroenterol Hepatol 2021;15:139-47. [PMID: 32902336 DOI: 10.1080/17474124.2020.1815532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Persico M, Masarone M, Damato A, Ambrosio M, Federico A, Rosato V, Bucci T, Carrizzo A, Vecchione C. "Non alcoholic fatty liver disease and eNOS dysfunction in humans". BMC Gastroenterol 2017;17:35. [PMID: 28264657 DOI: 10.1186/s12876-017-0592-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
38 Su T, Yang Y, Lai S, Jeong J, Jung Y, McConnell M, Utsumi T, Iwakiri Y. Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis. Cell Mol Gastroenterol Hepatol 2021;11:1139-61. [PMID: 33340713 DOI: 10.1016/j.jcmgh.2020.12.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
39 Sheen JM, Chen YC, Tain YL, Huang LT. Increased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model. Int J Mol Sci. 2014;15:3989-4006. [PMID: 24603538 DOI: 10.3390/ijms15033989] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
40 Kimer N, Pedersen JS, Busk TM, Gluud LL, Hobolth L, Krag A, Møller S, Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 2017;65:592-603. [PMID: 27775818 DOI: 10.1002/hep.28898] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
41 Pu Y, Zhang S, Zhou R, Huang N, Li H, Wei W, Li L, Huang C, Yang J, Li Z. IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS/p38 signal pathway. Biochemical and Biophysical Research Communications 2016;470:41-7. [DOI: 10.1016/j.bbrc.2015.12.093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
42 Macías-rodríguez RU, Duarte-rojo A, Cantú-brito C, Sauerbruch T, Ruiz-margáin A, Trebicka J, Green-gómez M, Díaz Ramírez JB, Sierra Beltrán M, Uribe-esquivel M, Torre A. Cerebral haemodynamics in cirrhotic patients with hepatic encephalopathy. Liver Int 2015;35:344-52. [DOI: 10.1111/liv.12557] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
43 Du QH, Han L, Jiang JJ, Xu Y, Li WH, Li PT, Wang XY, Jia X. Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats. World J Gastroenterol. 2014;20:16674-16682. [PMID: 25469036 DOI: 10.3748/wjg.v20.i44.16674] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 La Mura V, Pasarín M, Rodriguez-Vilarrupla A, García-Pagán JC, Bosch J, Abraldes JG. Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase. J Hepatol. 2014;61:1321-1327. [PMID: 25038487 DOI: 10.1016/j.jhep.2014.07.014] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
45 Eisinger K, Krautbauer S, Wiest R, Karrasch T, Hader Y, Scherer MN, Farkas S, Aslanidis C, Buechler C. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest. 2013;43:926-932. [PMID: 23855493 DOI: 10.1111/eci.12122] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
46 Sanchez-jimenez B, Chavez-tapia NC, Jakobsen JC, Nikolova D, Gluud C; Cochrane Hepato-Biliary Group. Antibiotic prophylaxis for people with cirrhosis and variceal bleeding. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013214] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Wei W, Pu YS, Wang XK, Jiang A, Zhou R, Li Y, Zhang QJ, Wei YJ, Chen B, Li ZF. Wall shear stress in portal vein of cirrhotic patients with portal hypertension. World J Gastroenterol 2017;23:3279-86. [PMID: 28566887 DOI: 10.3748/wjg.v23.i18.3279] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
48 Kimer N, Gudmann NS, Pedersen JS, Møller S, Nielsen MJ, Leeming DJ, Karsdal MA, Møller HJ, Bendtsen F, Grønbæk H. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. PLoS One 2018;13:e0203200. [PMID: 30183743 DOI: 10.1371/journal.pone.0203200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Fleming MM, Liu F, Zhang Y, Pei KY. Model for End-Stage Liver Disease Underestimates Morbidity and Mortality in Patients with Ascites Undergoing Colectomy. World J Surg 2018;42:3390-7. [PMID: 29541825 DOI: 10.1007/s00268-018-4591-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Uyar A, Yaman T. Evaluation with endothelial nitric oxide synthase (eNOS) immunoreactivity of the protective role of astaxanthin on hepatorenal injury of remote organs caused by ischaemia reperfusion of the lower extremities. Prz Gastroenterol 2020;15:161-72. [PMID: 32550950 DOI: 10.5114/pg.2019.88620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol 2014;20:15499-517. [PMID: 25400435 DOI: 10.3748/wjg.v20.i42.15499] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
52 Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18:281-291. [PMID: 24679494 DOI: 10.1016/j.cld.2013.12.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 76] [Article Influence: 14.7] [Reference Citation Analysis]
53 Møller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci 2015;60:3209-25. [DOI: 10.1007/s10620-015-3752-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
54 Jun JH, Choi JH, Bae SH, Oh SH, Kim GJ. Decreased C-reactive protein induces abnormal vascular structure in a rat model of liver dysfunction induced by bile duct ligation. Clin Mol Hepatol 2016;22:372-81. [PMID: 27729629 DOI: 10.3350/cmh.2016.0032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Abdel-Razik A, Mousa N, Elhelaly R, Elzehery R, Hasan AS, Abdelsalam M, Seif AS, Tawfik AM, El-Wakeel N, Eldars W. Helicobacter pylori as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study. Front Med (Lausanne) 2020;7:96. [PMID: 32266280 DOI: 10.3389/fmed.2020.00096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
56 Wu Q, Shen L, Chu J, Ma X, Jin B, Meng F, Chen J, Wang Y, Wu L, Han J. Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis. Oncol Lett. 2015;9:347-350. [PMID: 25435990 DOI: 10.3892/ol.2014.2626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
57 Boregowda U, Umapathy C, Halim N, Desai M, Nanjappa A, Arekapudi S, Theethira T, Wong H, Roytman M, Saligram S. Update on the management of gastrointestinal varices. World J Gastrointest Pharmacol Ther. 2019;10:1-21. [PMID: 30697445 DOI: 10.4292/wjgpt.v10.i1.1] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
58 Namba M, Kawaoka T, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Baba Y, Awai K, Chayama K. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. Clin J Gastroenterol 2019;12:341-6. [PMID: 30706429 DOI: 10.1007/s12328-019-00938-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, Marchiori RC, Rezende GF. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis. 2015;47:957-963. [PMID: 26321186 DOI: 10.1016/j.dld.2015.07.156] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
60 Kondo R, Kage M, Iijima H, Fujimoto J, Nishimura T, Aizawa N, Akiba J, Naito Y, Kusano H, Nakayama M, Mihara Y, Tanigawa M, Yano H. Pathological findings that contribute to tissue stiffness in the spleen of liver cirrhosis patients. Hepatol Res 2018;48:1000-7. [PMID: 29766631 DOI: 10.1111/hepr.13195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
61 Tee JK, Ng LY, Koh HY, Leong DT, Ho HK. Titanium Dioxide Nanoparticles Enhance Leakiness and Drug Permeability in Primary Human Hepatic Sinusoidal Endothelial Cells. Int J Mol Sci 2018;20:E35. [PMID: 30577655 DOI: 10.3390/ijms20010035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
62 Nascimento M, Piran R, Da Costa RM, Giordani MA, Carneiro FS, Aguiar DH, Dias MC, Sugizaki MM, Luvizotto RA, Nascimento AF, Bomfim GF. Hepatic injury induced by thioacetamide causes aortic endothelial dysfunction by a cyclooxygenase-dependent mechanism. Life Sci 2018;212:168-75. [PMID: 30292829 DOI: 10.1016/j.lfs.2018.09.051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
63 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014;34:1153-63. [DOI: 10.1111/liv.12549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
64 Stanhewicz AE, Nuckols VR, Pierce GL. Maternal microvascular dysfunction during preeclamptic pregnancy. Clin Sci (Lond) 2021;135:1083-101. [PMID: 33960392 DOI: 10.1042/CS20200894] [Reference Citation Analysis]
65 Forkin KT, Colquhoun DA, Nemergut EC, Huffmyer JL. The Coagulation Profile of End-Stage Liver Disease and Considerations for Intraoperative Management. Anesth Analg 2018;126:46-61. [PMID: 28795966 DOI: 10.1213/ANE.0000000000002394] [Cited by in Crossref: 32] [Cited by in F6Publishing: 4] [Article Influence: 10.7] [Reference Citation Analysis]
66 Salem ML, Zidan AA, Attia M, El-Naggar RE, Nassef M, Abou El-Azm AR, El-Bate H, Yussif M, Galal S, Abo Senna M, El Demellawy M. IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS. Immunopharmacol Immunotoxicol 2017;39:188-98. [PMID: 28472907 DOI: 10.1080/08923973.2017.1320670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Hollenbach M. The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC). Int J Mol Sci 2017;18:E2466. [PMID: 29156655 DOI: 10.3390/ijms18112466] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
68 Torok NJ. Dysregulation of redox pathways in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2016;311:G667-74. [PMID: 27562057 DOI: 10.1152/ajpgi.00050.2016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
69 Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol. 2014;61:912-924. [PMID: 24911462 DOI: 10.1016/j.jhep.2014.05.047] [Cited by in Crossref: 162] [Cited by in F6Publishing: 131] [Article Influence: 23.1] [Reference Citation Analysis]
70 Klindt C, Reich M, Hellwig B, Stindt J, Rahnenführer J, Hengstler JG, Köhrer K, Schoonjans K, Häussinger D, Keitel V. The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver. Cells 2019;8:E1467. [PMID: 31752395 DOI: 10.3390/cells8111467] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
71 Purnak T, Beyazit Y, Ibis M, Koklu S, Efe C, Ozaslan E, Ciftci A, Tenlik I. The involvement of nitric oxide in the physiopathology of hepatoportal sclerosis. Clinical Biochemistry 2012;45:1450-4. [DOI: 10.1016/j.clinbiochem.2012.07.091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
72 Sanchez-jimenez B, Chavez-tapia NC, Jakobsen JC, Nikolova D, Gluud C; Cochrane Hepato-Biliary Group. Antibiotic prophylaxis versus placebo or no intervention for people with cirrhosis and variceal bleeding. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013175] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Bettinger D, Sturm L, Pfaff L, Hahn F, Kloeckner R, Volkwein L, Praktiknjo M, Lv Y, Han G, Huber JP, Boettler T, Reincke M, Klinger C, Caca K, Heinzow H, Seifert LL, Weiss KH, Rupp C, Piecha F, Kluwe J, Zipprich A, Luxenburger H, Neumann-Haefelin C, Schmidt A, Jansen C, Meyer C, Uschner FE, Brol MJ, Trebicka J, Rössle M, Thimme R, Schultheiss M. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. J Hepatol 2021;74:1362-72. [PMID: 33508376 DOI: 10.1016/j.jhep.2021.01.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
74 Simonetto DA, Yang HY, Yin M, de Assuncao TM, Kwon JH, Hilscher M, Pan S, Yang L, Bi Y, Beyder A. Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces. Hepatology. 2015;61:648-659. [PMID: 25142214 DOI: 10.1002/hep.27387] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 15.2] [Reference Citation Analysis]
75 Yoshida H, Shimizu T, Yoshioka M, Taniai N. Management of portal hypertension based on portal hemodynamics. Hepatol Res 2021;51:251-62. [PMID: 33616258 DOI: 10.1111/hepr.13614] [Reference Citation Analysis]
76 Bravo M, Raurell I, Hide D, Fernández-Iglesias A, Gil M, Barberá A, Salcedo MT, Augustin S, Genescà J, Martell M. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. Sci Rep 2019;9:20183. [PMID: 31882668 DOI: 10.1038/s41598-019-56366-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
77 Sacerdoti D, Pesce P, Di Pascoli M, Brocco S, Cecchetto L, Bolognesi M. Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat. 2015;120:80-90. [PMID: 26072731 DOI: 10.1016/j.prostaglandins.2015.05.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
78 Kawanaka H, Akahoshi T, Kinjo N, Iguchi T, Ninomiya M, Yamashita YI, Ikegami T, Yoshizumi T, Shirabe K, Maehara Y. Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension. Br J Surg 2014;101:1585-93. [PMID: 25200126 DOI: 10.1002/bjs.9622] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
79 Aller MA, Blanco-Rivero J, Arias JI, Balfagon G, Arias J. The wound-healing response and upregulated embryonic mechanisms: brothers-in-arms forever. Exp Dermatol. 2012;21:497-503. [PMID: 22716244 DOI: 10.1111/j.1600-0625.2012.01525.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
80 Yao H, Zhang C. Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. Ir J Med Sci 2018;187:925-34. [DOI: 10.1007/s11845-018-1765-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Jiang B, Deng Q, Huo Y, Li W, Shibuya M, Luo J. Endothelial Gab1 deficiency aggravates splenomegaly in portal hypertension independent of angiogenesis. Am J Physiol Gastrointest Liver Physiol 2015;308:G416-26. [PMID: 25501549 DOI: 10.1152/ajpgi.00292.2014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
82 Stommel MW, Strik C, van Goor H. Response to pathological processes in the peritoneal cavity—Sepsis, tumours, adhesions, and ascites. Seminars in Pediatric Surgery 2014;23:331-5. [DOI: 10.1053/j.sempedsurg.2014.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
83 Kilmister EJ, Paterson C, Brasch HD, Davis PF, Tan ST. The Role of the Renin-Angiotensin System and Vitamin D in Keloid Disorder-A Review. Front Surg 2019;6:67. [PMID: 32039229 DOI: 10.3389/fsurg.2019.00067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
84 Wang H, Meng X, Chen M, Xu S, Zhu M, Lu X, Wu F, Yu W. Bile acids elicited endothelium-dependent vasoconstrictor hypo-activity through TRPV4 channels in the thoracic aorta of bile duct ligation rats. Biomedicine & Pharmacotherapy 2019;109:511-8. [DOI: 10.1016/j.biopha.2018.10.151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Paternostro R, Reiberger T, Mandorfer M, Schwarzer R, Schwabl P, Bota S, Ferlitsch M, Trauner M, Peck-radosavljevic M, Ferlitsch A. Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis: Plasma renin concentration and cirrhosis. Journal of Gastroenterology and Hepatology 2017;32:184-90. [DOI: 10.1111/jgh.13439] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
86 Ostadhadi S, Rezayat SM, Ejtemaei-Mehr S, Tavangar SM, Nikoui V, Jazaeri F, Eftekhari G, Abdollahi A, Dehpour AR. Mesenteric artery responsiveness to acetylcholine and phenylephrine in cirrhotic rats challenged with endotoxin: the role of TLR4. Can J Physiol Pharmacol 2015;93:475-83. [PMID: 25978623 DOI: 10.1139/cjpp-2014-0515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
87 La Mura V, Pasarín M, Meireles CZ, Miquel R, Rodríguez-Vilarrupla A, Hide D, Gracia-Sancho J, García-Pagán JC, Bosch J, Abraldes JG. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology. 2013;57:1172-1181. [PMID: 23184571 DOI: 10.1002/hep.26127] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
88 Cong M, Iwaisako K, Jiang C, Kisseleva T. Cell signals influencing hepatic fibrosis. Int J Hepatol. 2012;2012:158547. [PMID: 22973518 DOI: 10.1155/2012/158547] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
89 Sacerdoti D, Mania D, Jiang H, Pesce P, Gaiani S, Gatta A, Bolognesi M. Increased EETs participate in peripheral endothelial dysfunction of cirrhosis. Prostaglandins Other Lipid Mediat 2012;98:129-32. [PMID: 22245571 DOI: 10.1016/j.prostaglandins.2011.12.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
90 Wang L, Zhao X, Feng Y, Ma X, Wu H, Zhu Q. Intrahepatic angiogenesis increases portal hypertension in hepatitis B patients with cirrhosis. Hepatol Res 2017;47:E94-E103. [PMID: 27115574 DOI: 10.1111/hepr.12732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Kukla M, Waluga M, Żorniak M, Berdowska A, Wosiewicz P, Sawczyn T, Bułdak RJ, Ochman M, Ziora K, Krzemiński T, Hartleb M. Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis. World J Gastroenterol 2017;23:2613-24. [PMID: 28465646 DOI: 10.3748/wjg.v23.i14.2613] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]